Btw, the reason I posted Grok's summary above, is that it might give us a glimpse into how CORE-NK is tracking compared to the two SOC drugs (alone) that CORE-NK is being combined with and in context with the patient population being treated.This distinction matters for AML patients ineligible for transplants, as aza/ven offers a less toxic alternative to intensive regimens like FLAG-IDA, but it’s not entirely free of chemo-like side effects.
Ann: ADVENT-AML Phase 1B clinical trial update, page-40
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.4¢ | $15.69K | 3.919M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 26 | 21936206 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 24685267 | 27 |
View Market Depth
| Last trade - 16.10pm 13/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |